I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Radioiodine (^131^ I) is given under TSH stimulation to perform a whole-body scan (WBS) or ablate any remaining cancer cells and thyroid tissue in patients with differentiated thyroid cancer (DTC) after total thyroidectomy. Sodium-iodide symporter (NIS) expression at the plasma membrane in the thyroid follicular cell constitutes the basis of RAIT for hyperthyroidism and DTC.\[[@ref1][@ref2]\] Despite the physiological and clinical relevance of NIS plasma membrane expression, less is known regarding the molecular mechanisms underlying NIS transport to the plasma membrane. TSH constitutes the primary regulator of NIS expression in the thyroid follicular cell by not only stimulating NIS expression at the transcriptional level, but it is also required at post-translational levels for targeting NIS to, and/or retaining it, the plasma membrane.\[[@ref1][@ref2]\]

In the setting of^131^ I treatment of remnant, or residual tumor, or metastatic disease, thyroid hormone withdrawal remains the standard approach in raising TSH levels for adequate radioiodine uptake. As a convention with the aim to reduce circulating free thyroxine (T4) levels below the normal range, thyroid hormone is withdrawn 3--4 weeks prior RAIT.\[[@ref3]\] After thyroidectomy or cessation of T4 therapy, the patient\'s serum-T4 concentration should decline sufficiently to allow the serum-TSH concentration to rise above 25 to 30 mU/L.\[[@ref4]\] As a consequence, patients with DTC may be exposed to repeated and prolonged periods of hypothyroidism that affect their quality of life and may increase the potential for tumor growth. To minimize the severe discomfort due to gross hypothyroidism, recombinant human (rhTSH) has been used for enhancing radioiodine uptake while the patient is continued on thyroxine replacement. The cost of rhTSH therapy precludes routine use in DTC patients, especially, in a resource-constrained setting such as India. In some centers, patients are placed on 50% dose of thyroxine while in others, Triiodothyronine (LT3) (not easily available in India) is used during the TSH withdrawal protocols. Previous studies have shown that there is an exponential rise of TSH after thyroidectomy or thyroid hormone withdrawal and TSH rise occurred much earlier than 4 weeks.\[[@ref5][@ref6][@ref7]\] In this case one might able to expedite the^131^ I-WBS scan and therapy in these patients and minimize their morbidity related to hypothyroidism.

A[IMS]{.smallcaps} {#sec1-2}
==================

To study the time taken for TSH to rise after total thyroidectomy in patients operated for DTC.

S[UBJECTS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-3}
================================================

Following the Institutional review board (IRB) and ethics committee approval, we were able to recruit 40 patients, undergoing total or near-total thyroidectomy, for DTC which was confirmed by histopathology. All consecutive patients who underwent total thyroidectomy for known differentiated thyroid cancer (based on fine-needle aspiration cytology, FNAC) were explained about the study. Of those patients, who gave informed written consent and patients whose histopathology confirmed differentiated thyroid cancer (papillary and follicular thyroid cancer, PTC) and planned for RAIT/scan were included in the study. Postoperative blood samples for TSH were collected weekly until a result of TSH ≥30 was obtained. TSH was performed using electro-chemiluminescence assay. Free thyroid hormones were not done postoperatively. All surgeries were done by a single surgeon (Author DS).

S[AMPLE]{.smallcaps} S[IZE AND]{.smallcaps} S[TATISTICS]{.smallcaps} {#sec1-4}
====================================================================

Considering TSH elevation after thyroidectomy or thyroid hormone withdrawal, previous studies have studied sample sizes ranging from 13--25\[[@ref5][@ref6][@ref7]\] and TSH levels were checked once a week or once in 3--4 days. Data are presented as mean ± SD. Mann-Whitney test was used for comparison among continuous variables. Statistical analysis was done in Microsoft Excel (version Office 365) and SPSS version 15.

R[ESULTS]{.smallcaps} {#sec1-5}
=====================

The data of all the patients are shown in [Table 1](#T1){ref-type="table"}. The mean (SD) age of the cohort was 40 (13) years with 35 females (88%) and their mean (SD) preoperative TSH was 3.6 (1.35) mIU/L. Of the 40 subjects, 39 had papillary thyroid cancer (PTC) wherein 32 had classical variant and 7 had follicular variants of PTC and one had follicular thyroid cancer (FTC). Of those with 39 PTC, 20 had a prophylactic central compartment lymph node dissection (CCLND), 10 had therapeutic CCLND and 9 did not undergo CCLND. Only one patient of FTC had total thyroidectomy. Of those 10 subjects who underwent therapeutic CCLND, 6 underwent therapeutic lateral lymph node dissection (4 unilateral and 2 bilateral). None had distant metastatic disease at the time of diagnosis and during the initial whole body-iodine scan. Of the 40 patients included, 8 had high TPO levels. Of those 8 patients, 5 had TSH level \<10 mIU/l and were on thyroxine replacement. But during surgery, all the 40 patients were euthyroid and TSH was within normal reference range. At the end of the first week postoperatively, the mean TSH of the cohort was 24.25 (6) with 8 patients (20%) achieving the required cut-off of TSH ≥30 mIU/L and 30 patients (75%) achieving TSH level ≥20 mIU/L. The 8 patients (6 females) whose levels rose to ≥30 mIU/L by the end of the first week, had a mean age of 42 (14) years, a mean preoperative TSH of 4 (1.45) which was not statistically different from those whose level did not rise \[mean TSH of 3.5 (1.5, *P* = 0.4)\]. At the end of the second week, the mean TSH was 53 (17) with all patients (100%) achieving a TSH level \>30 mIU/L.

###### 

Data of the 40 patients with presentation characteristics and type of surgery and final histopathology

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *n*   Age (yrs)   Sex   Preop TSH   Mode of Presentation   Type of Surgery      TSH 1\            TSH 2\             TSH 3\             TSH 4\             FINAL HPE
                                                                                  (7 days postop)   (14 days postop)   (21 days postop)   (28 days postop)   
  ----- ----------- ----- ----------- ---------------------- -------------------- ----------------- ------------------ ------------------ ------------------ -----------
  1     26          f     3.2         STN                    TT                   18                40                 70                 \>100              PTC

  2     45          f     2.1         MNG                    TT                   27                70                 \>100              \>100              PTC

  3     36          f     1.8         STN                    TT+CCLND             23                36                 82                 \>150              PTC

  4     62          f     4.2         STN with lymph nodes   TT+CCLND+left MRND   21                46                 89                 \>150              PTC

  5     51          m     3.9         STN                    TT                   27                56                 \>100              \>100              PTC

  6     32          f     4.1         MNG                    TT+CCLND             20                45                 92                 \>150              FVPTC

  7     41          f     2.5         STN                    TT+CCLND             19                38                 85                 108                PTC

  8     28          f     1.9         STN                    TT+CCLND             26                32                 72                 120                PTC

  9     51          f     4.6         STN                    TT+CCLND             22                42                 82                 128                PTC

  10    42          f     5.2         STN                    TT+CCLND             26                38                 72                 130                FVPTC

  11    40          m     3.6         MNG                    TT+CCLND             19                41                 68                 124                PTC

  12    32          f     4.1         MNG                    TT                   22                37                 80                 132                PTC

  13    41          f     2.9         STN with lymph nodes   TT+CCLND+B/L MRND    26                42                 100                \>140              PTC

  14    49          m     3.2         STN                    TT+CCLND             30                40                 82                 \>100              PTC

  15    42          f     1           MNG                    TT                   19                38                 59                 82                 FVPTC

  16    19          f     2.1         MNG                    TT                   16                60                 78                 126                PTC

  17    22          f     1.8         STN with lymph nodes   TT+Rt MRND           22                42                 68                 80                 PTC

  18    71          f     5.4         STN                    TT+CCLND             30                48                 60                 89                 PTC

  19    18          f     0.9         MNG                    TT                   28                51                 72                 \>100              FVPTC

  20    45          f     4.8         MNG                    TT+CCLND             26                60                 78                 94                 PTC

  21    42          f     3.8         STN                    TT                   18                42                 76                 \>100              PTC

  22    32          f     4.1         MNG with lymph nodes   TT+CCLND+left MRND   23                58                 90                 \>100              PTC

  23    42          m     1.6         MNG                    TT                   30                44                 80                 \>100              PTC

  24    31          f     4.9         STN                    TT+CCLND             31                89                 \>100              \>100              PTC

  25    50          f     2.9         STN                    TT                   36                102                \>150              \>150              FTC

  26    32          f     6.1         STN                    TT+CCLND             38                78                 \>150              \>150              PTC

  27    38          f     4.1         MNG                    TT+CCLND             40                68                 \>100              \>100              PTC

  28    62          f     5.9         MNG                    TT+CCLND             19                58                 \>100              \>100              PTC

  29    31          f     3.7         MNG with lymph nodes   TT+CCLND+B/L MRND    24                64                 98                 \>150              PTC

  30    30          f     5.2         STN                    TT+CCLND             29                72                 \>150              \>150              PTC

  31    56          f     4.5         STN                    TT+CCLND             21                34                 68                 130                PTC

  32    49          m     2.9         MNG                    TT+CCLND             19                40                 \>100              \>100              FVPTC

  33    28          f     4.8         STN                    TT+CCLND             22                32                 80                 \>100              PTC

  34    39          f     5.1         STN with lymph nodes   TT+CCLND+left MRND   18                42                 79                 \>100              FVPTC

  35    48          f     1.8         MNG                    TT+CCLND             21                38                 \>100              \>100              FVPTC

  36    18          f     3.7         STN                    TT+CCLND             22                48                 \>100              \>100              PTC

  37    28          f     4.1         MNG                    TT+CCLND             31                41                 \>100              \>100              PTC

  38    41          f     3.7         MNG                    TT+CCLND             24                38                 69                 98                 PTC

  39    49          f     2.9         STN                    TT+CCLND             15                38                 55                 77                 PTC

  40    61          f     5.1         STN                    TT+CCLN\             22                31                 49                 94                 PTC
                                                             D                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------

STN: Solitary Thyroid nodule; MNG: Multinodular goiter; TT: Total Thyroidectomy; CCLND: Central Compartment Neck Dissection; MRND: Modified Radical Neck Dissection; PTC: Papillary thyroid cancer (Classic); FVPTC: Follicular Variant Papillary thyroid cancer; FTC: Follicular Thyroid cancer, Post-op: Postoperative, Preop: Preoperative

D[ISCUSSION]{.smallcaps} {#sec1-6}
========================

We noted that it took between 7--14 days to achieve a TSH level of ≥30 mIU/L post-thyroidectomy. According to recommendation 53 from the ATA guidelines,\[[@ref3]\] "If thyroid hormone withdrawal is planned prior RAIT or diagnostic testing, levothyroxine (LT4) should be withdrawn for 3--4 weeks. LT3 may be substituted for LT4 in the initial weeks and LT3 should be withdrawn for at least 2 weeks. Serum TSH should be measured prior radioisotope administration to evaluate the degree of TSH elevation (strong recommendation, moderate-quality evidence). A goal TSH of \>30 mIU/L has been generally adopted in preparation for RAIT or diagnostic testing". However these data are based on the previous study where TSH was initially measured 3 weeks after the surgery and did not look in sequential TSH measurements after thyroidectomy\[[@ref8]\] and ever since this time duration of 3--4 weeks has been followed as a convention in the Nuclear Medicine Departments of the institutes and hospitals. There are three studies in the literature that clearly suggest TSH elevation occurs exponentially after thyroidectomy or thyroid hormone withdrawal. In a study by Serhal et al., serum-TSH concentrations reached \>30 mU/L 8--26 (mean ± SD, 14.2 ± 4.8) d after thyroidectomy or 9--29 (18.1 ± 4.1) d after T4 withdrawal.\[[@ref5]\] That level of TSH elevation was achieved 18 d after thyroidectomy and 22 d after T4 withdrawal in more than 95% of patients. In another study by Leboeuf et al.,\[[@ref6]\] the time needed to reach a TSH level \>30 mUI/L was 17 ± 9 d and was significantly longer in patients on T3 (32 ± 4 d; *P* = 0.006). Liel et al. showed that in 13 patients on suppressive doses of thyroxine, on 15 separate occasions, baseline TSH levels were between 0.01 and 0.4 mIU/L.\[[@ref7]\] The mean interval required to reach the target TSH concentration of at least 30 mIU/L was 17 days (95% CI 15--19; range 11--28 days). Our study replicates the same finding that by 2 weeks wherein all patients attained target TSH \>30mIU/L.

This poses the question; do patients really have to wait for 3--4 weeks for their radioiodine scan? TSH constitutes the primary regulator of NIS expression in the thyroid follicular cell by not only stimulating NIS expression at the transcriptional level, but it is also required at post-translational levels for targeting NIS to, and/or retaining it at, the plasma membrane. The molecular mechanism regulating TSH-stimulated NIS transport to, retention at, and removal from the plasma membrane remains unknown. In functional thyroid cells (FRTL-5) of rat, immunofluorescence analysis demonstrated that after TSH withdrawal, NIS molecules located in the plasma membrane are redistributed to uncharacterized intracellular compartments.\[[@ref9]\] TSH may also play a role in phosphorylation of proteins and the activation of several protein kinases, which might constitute a post-translational modification involved in the NIS intracellular transport process.\[[@ref10]\] Thus it may not be for "TSH elevation" that we are waiting for but for the complete effect of the "TSH elevation on the NIS expression".

DTC often exhibit reduced (or even undetectable) iodide transport compared with normal thyroid tissue, and they are diagnosed as cold nodules on thyroid scintigraphy. Hence one may argue about the prolonged wait for a good 4 weeks to improve NIS expression on the follicular cells of the residual thyroid and cancer cells, which needs activation of intracellular protein machinery after elevations of TSH and its action on TSH receptor. However rhTSH-based protocols are done in a very short time of 2--5 days after administration of rhTSH with equal diagnostic and therapeutic efficacy, thus reducing the need for prolonged wait.

Based on our study we suggest a waiting time of 10--14 days after thyroidectomy by a high-volume thyroid surgeon for iodine scan rather than conventional wait time of 3--4 weeks. The strength of the study was a single surgeon (author DS), who operated all the patients, so the degree of remnant thyroid affecting the TSH levels was consistent. The limitation of our study is that we did not include patients on suppressive doses of thyroxine to see when they attain TSH level ≥30 mIU/L after cessation of T4 therapy. We also did not have sufficient people for comparison with or without TPO positivity---to observe if this was a factor in the rate of rising TSH. We also have not compared^131^ I-WBS at an earlier period (done at 10--14 days) with the traditional scan at the end of 4 weeks to observe if it made any difference in the intensity of uptake.

C[ONCLUSION]{.smallcaps} {#sec1-7}
========================

^131^ I-WBS can be performed in 10--14 days after total thyroidectomy instead of the usual wait time of 4 weeks. This could improve patient QOL and avoid complications related to prolonged hypothyroidism.
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